| 5.2 1.69 (48.15%) | 09-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 7.98 | 1-year : | 10.39 |
| Resists | First : | 6.83 | Second : | 8.89 |
| Pivot price | 4.32  |
|||
| Supports | First : | 3.5 | Second : | 2.91 |
| MAs | MA(5) : | 4.14 |
MA(20) : | 4.4 |
| MA(100) : | 8.75 |
MA(250) : | 47.98 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 17.7 |
D(3) : | 17.1 |
| RSI | RSI(14): 46.5 |
|||
| 52-week | High : | 180 | Low : | 3.24 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TNFA ] has closed above bottom band by 42.9%. Bollinger Bands are 60% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 26 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 4.51 - 4.53 | 4.53 - 4.55 |
| Low: | 4.03 - 4.04 | 4.04 - 4.06 |
| Close: | 4.16 - 4.19 | 4.19 - 4.22 |
TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
Wed, 24 Sep 2025
TNF Pharmaceuticals Stock More Than Doubles After Announcing Name Change To Represent Pivot Into Quantum-Class Computing - Stocktwits
Wed, 24 Sep 2025
TNF Pharmaceuticals rebrands as Q/C Technologies, changes ticker to QCLS - Investing.com
Wed, 24 Sep 2025
TNF Pharmaceuticals stock soars after strategic pivot to quantum computing - Investing.com
Mon, 08 Sep 2025
TNF Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Yahoo Finance
Thu, 04 Sep 2025
TNF Pharmaceuticals Announces Closing of $7 Million Private Placement - Business Wire
Thu, 04 Sep 2025
TNF Pharmaceuticals raises $7 million in private placement at premium - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 311 (K) |
| Shares Short P.Month | 52 (K) |
| EPS | -202 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 17.46 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -24 % |
| Return on Equity (ttm) | -115.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.03 |
| PEG Ratio | 0 |
| Price to Book value | 0.23 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.84 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|